Detalhe da pesquisa
1.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Blood
; 141(16): 1971-1981, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626583
2.
IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer.
Chin J Cancer Res
; 36(2): 103-113, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751442
3.
Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.
BMC Cancer
; 18(1): 520, 2018 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29724167
4.
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Oncologist
; 21(9): 1085-90, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27401892
5.
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Gastric Cancer
; 18(1): 168-76, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24557418
6.
Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015-2017): A multicentre prospective study.
Lancet Reg Health West Pac
; 23: 100452, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35465042
7.
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Lancet Respir Med
; 7(5): 437-446, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30981696